In the third quarter, Geneos Wealth Management Inc. sold 1,511 shares of Northrop Grumman, cutting its position by 61.6% to just 943 shares. The remaining stake was valued at $575,000 at quarter-end. This move contrasts with several smaller institutional investors that initiated or increased positions during the same period. Parvin Asset Management and Twin Peaks Wealth Advisors each built new stakes worth roughly $25,000–$31,000. NewSquare Capital boosted its holdings by 75%, adding 27 shares to reach 63 shares, while AlphaQuest and City Holding more than doubled smaller positions, bringing their stakes to 93 and 100 shares respectively. Despite Geneos’s reduction, hedge funds and other institutions continue to hold 83.4% of the company’s stock.

Insiders have liquidated a total of 10,097 shares over the past three months, generating proceeds of approximately $6.1 million. Director Mark A. Welsh III offloaded 97 shares in late November, trimming his stake by 2.22% to 4,281 shares. CEO Kathy J. Warden sold 7,000 shares in early January, reducing her ownership by 3.47% to 194,602 shares. Insider ownership now stands at 0.23% of the total share count, reflecting a modest but noteworthy increase in executive sales ahead of year-end reporting.

Northrop Grumman reported third-quarter earnings per share of $7.67, exceeding consensus estimates by $1.24, on revenue of $10.42 billion, a 4.3% year-over-year increase but slightly below analyst forecasts. Return on equity reached 25.49% and net margin held at 9.82%. Management reiterated full-year 2025 EPS guidance in the range of $25.65 to $26.05 and analysts collectively project $28.05 for the current fiscal year. These figures highlight resilience in core defense programs despite modest headwinds in top-line growth.

The company paid a quarterly dividend of $2.31 per share on December 17, marking an annualized payout of $9.24 and a yield of 1.5%. The dividend payout ratio stands at 33.24%. On the research front, two firms have assigned Strong Buy ratings, twelve maintain Buy ratings and seven have Hold ratings, resulting in a consensus Moderate Buy recommendation. The average price target sits near $647, reflecting roughly 5% upside from current trading levels and suggesting limited but positive return potential over the next 12 months.